Rafarma Pharmaceuticals Retained Earnings vs. Price To Earning
| RAFA Stock | USD 0.09 0.03 47.54% |
For Rafarma Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Rafarma Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Rafarma Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Rafarma Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Rafarma Pharmaceuticals over time as well as its relative position and ranking within its peers.
Rafarma |
Rafarma Pharmaceuticals Price To Earning vs. Retained Earnings Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Rafarma Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Rafarma Pharmaceuticals value to that of its competitors to determine the firm's financial worth. Rafarma Pharmaceuticals is currently regarded as top stock in retained earnings category among its peers. It also is currently regarded as top stock in price to earning category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Rafarma Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Rafarma Pharmaceuticals' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Rafarma Price To Earning vs. Retained Earnings
Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
Rafarma Pharmaceuticals |
| = | (2.38 M) |
Retained Earnings shows how the firm utilizes its profits over time. In simple terms, investors can think of retained earnings as the amount of profit the company has reinvested in the business since its inceptions. However the methodology to make a decision over how much profit to retain is different between companies in different industries. For example, growing industries tend to retain more of their earnings than more matured industries as they need more assets investment to sustain their growth.
Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Rafarma Pharmaceuticals |
| = | (1.29) X |
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
Rafarma Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Rafarma Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Rafarma Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Rafarma Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Rafarma Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Rafarma Pharmaceuticals, Inc., a multi-product pharmaceutical company, produces and sells drugs, generic antibiotics, and specialty pharmaceuticals in Russia. As of October 19, 2020, Rafarma Pharmaceuticals, Inc. operates as a subsidiary of R. D. RAFARMA PHARMACEUTICALS operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange.
Rafarma Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Rafarma Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Rafarma Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Rafarma Pharmaceuticals' important profitability drivers and their relationship over time.
Use Rafarma Pharmaceuticals in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Rafarma Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Rafarma Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Rafarma Pharmaceuticals Pair Trading
Rafarma Pharmaceuticals Pair Trading Analysis
The ability to find closely correlated positions to Rafarma Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Rafarma Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Rafarma Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Rafarma Pharmaceuticals to buy it.
The correlation of Rafarma Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Rafarma Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Rafarma Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Rafarma Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Rafarma Pharmaceuticals position
In addition to having Rafarma Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Latest Gainers Thematic Idea Now
Latest Gainers
Dynamically computed list of top equities currently sorted across major exchanges. The Latest Gainers theme has 173 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Latest Gainers Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Rafarma Pink Sheet
To fully project Rafarma Pharmaceuticals' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Rafarma Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Rafarma Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows.